91 related articles for article (PubMed ID: 27732954)
21. Anaplastic lymphoma kinase: "Ligand Independent Activation" mediated by the PTN/RPTPβ/ζ signaling pathway.
Deuel TF
Biochim Biophys Acta; 2013 Oct; 1834(10):2219-23. PubMed ID: 23777859
[TBL] [Abstract][Full Text] [Related]
22. Phosphoproteomics reveals ALK promote cell progress via RAS/ JNK pathway in neuroblastoma.
Chen K; Lv F; Xu G; Zhang M; Wu Y; Wu Z
Oncotarget; 2016 Nov; 7(46):75968-75980. PubMed ID: 27732954
[TBL] [Abstract][Full Text] [Related]
23. Phosphoproteomic analysis of anaplastic lymphoma kinase (ALK) downstream signaling pathways identifies signal transducer and activator of transcription 3 as a functional target of activated ALK in neuroblastoma cells.
Sattu K; Hochgräfe F; Wu J; Umapathy G; Schönherr C; Ruuth K; Chand D; Witek B; Fuchs J; Li PK; Hugosson F; Daly RJ; Palmer RH; Hallberg B
FEBS J; 2013 Nov; 280(21):5269-82. PubMed ID: 23889739
[TBL] [Abstract][Full Text] [Related]
24. Integrated proximal proteomics reveals IRS2 as a determinant of cell survival in ALK-driven neuroblastoma.
Emdal KB; Pedersen AK; Bekker-Jensen DB; Lundby A; Claeys S; De Preter K; Speleman F; Francavilla C; Olsen JV
Sci Signal; 2018 Nov; 11(557):. PubMed ID: 30459283
[TBL] [Abstract][Full Text] [Related]
25. Phosphoproteome and gene expression profiling of ALK inhibition in neuroblastoma cell lines reveals conserved oncogenic pathways.
Van den Eynden J; Umapathy G; Ashouri A; Cervantes-Madrid D; Szydzik J; Ruuth K; Koster J; Larsson E; Guan J; Palmer RH; Hallberg B
Sci Signal; 2018 Nov; 11(557):. PubMed ID: 30459281
[TBL] [Abstract][Full Text] [Related]
26. Novel ALK inhibitor AZD3463 inhibits neuroblastoma growth by overcoming crizotinib resistance and inducing apoptosis.
Wang Y; Wang L; Guan S; Cao W; Wang H; Chen Z; Zhao Y; Yu Y; Zhang H; Pang JC; Huang SL; Akiyama Y; Yang Y; Sun W; Xu X; Shi Y; Zhang H; Kim ES; Muscal JA; Lu F; Yang J
Sci Rep; 2016 Jan; 6():19423. PubMed ID: 26786851
[TBL] [Abstract][Full Text] [Related]
27. A kinome-wide RNAi screen identifies ALK as a target to sensitize neuroblastoma cells for HDAC8-inhibitor treatment.
Shen J; Najafi S; Stäble S; Fabian J; Koeneke E; Kolbinger FR; Wrobel JK; Meder B; Distel M; Heimburg T; Sippl W; Jung M; Peterziel H; Kranz D; Boutros M; Westermann F; Witt O; Oehme I
Cell Death Differ; 2018 Dec; 25(12):2053-2070. PubMed ID: 29515255
[TBL] [Abstract][Full Text] [Related]
28. TKI sensitivity patterns of novel kinase-domain mutations suggest therapeutic opportunities for patients with resistant ALK+ tumors.
Amin AD; Li L; Rajan SS; Gokhale V; Groysman MJ; Pongtornpipat P; Tapia EO; Wang M; Schatz JH
Oncotarget; 2016 Apr; 7(17):23715-29. PubMed ID: 27009859
[TBL] [Abstract][Full Text] [Related]
29. The ALK/ROS1 Inhibitor PF-06463922 Overcomes Primary Resistance to Crizotinib in ALK-Driven Neuroblastoma.
Infarinato NR; Park JH; Krytska K; Ryles HT; Sano R; Szigety KM; Li Y; Zou HY; Lee NV; Smeal T; Lemmon MA; Mossé YP
Cancer Discov; 2016 Jan; 6(1):96-107. PubMed ID: 26554404
[TBL] [Abstract][Full Text] [Related]
30. High-throughput phosphoproteomics reveals in vivo insulin signaling dynamics.
Humphrey SJ; Azimifar SB; Mann M
Nat Biotechnol; 2015 Sep; 33(9):990-5. PubMed ID: 26280412
[TBL] [Abstract][Full Text] [Related]
31. ALK mutations confer differential oncogenic activation and sensitivity to ALK inhibition therapy in neuroblastoma.
Bresler SC; Weiser DA; Huwe PJ; Park JH; Krytska K; Ryles H; Laudenslager M; Rappaport EF; Wood AC; McGrady PW; Hogarty MD; London WB; Radhakrishnan R; Lemmon MA; Mossé YP
Cancer Cell; 2014 Nov; 26(5):682-94. PubMed ID: 25517749
[TBL] [Abstract][Full Text] [Related]
32. Integrating phosphoproteomics in systems biology.
Liu Y; Chance MR
Comput Struct Biotechnol J; 2014 Jul; 10(17):90-7. PubMed ID: 25349677
[TBL] [Abstract][Full Text] [Related]
33. Mechanisms of neuroblastoma regression.
Brodeur GM; Bagatell R
Nat Rev Clin Oncol; 2014 Dec; 11(12):704-13. PubMed ID: 25331179
[TBL] [Abstract][Full Text] [Related]
34. SAHA regulates histone acetylation, Butyrylation, and protein expression in neuroblastoma.
Xu G; Wang J; Wu Z; Qian L; Dai L; Wan X; Tan M; Zhao Y; Wu Y
J Proteome Res; 2014 Oct; 13(10):4211-9. PubMed ID: 25160476
[TBL] [Abstract][Full Text] [Related]
35. Phosphoproteome dynamics in onset and maintenance of oncogene-induced senescence.
de Graaf EL; Kaplon J; Zhou H; Heck AJ; Peeper DS; Altelaar AF
Mol Cell Proteomics; 2014 Aug; 13(8):2089-100. PubMed ID: 24961811
[TBL] [Abstract][Full Text] [Related]
36. Integrated proteomic analysis of post-translational modifications by serial enrichment.
Mertins P; Qiao JW; Patel J; Udeshi ND; Clauser KR; Mani DR; Burgess MW; Gillette MA; Jaffe JD; Carr SA
Nat Methods; 2013 Jul; 10(7):634-7. PubMed ID: 23749302
[TBL] [Abstract][Full Text] [Related]
37. Neuroblastoma: developmental biology, cancer genomics and immunotherapy.
Cheung NK; Dyer MA
Nat Rev Cancer; 2013 Jun; 13(6):397-411. PubMed ID: 23702928
[TBL] [Abstract][Full Text] [Related]
38. Safety and activity of crizotinib for paediatric patients with refractory solid tumours or anaplastic large-cell lymphoma: a Children's Oncology Group phase 1 consortium study.
Mossé YP; Lim MS; Voss SD; Wilner K; Ruffner K; Laliberte J; Rolland D; Balis FM; Maris JM; Weigel BJ; Ingle AM; Ahern C; Adamson PC; Blaney SM
Lancet Oncol; 2013 May; 14(6):472-80. PubMed ID: 23598171
[TBL] [Abstract][Full Text] [Related]
39. The ALK(F1174L) mutation potentiates the oncogenic activity of MYCN in neuroblastoma.
Berry T; Luther W; Bhatnagar N; Jamin Y; Poon E; Sanda T; Pei D; Sharma B; Vetharoy WR; Hallsworth A; Ahmad Z; Barker K; Moreau L; Webber H; Wang W; Liu Q; Perez-Atayde A; Rodig S; Cheung NK; Raynaud F; Hallberg B; Robinson SP; Gray NS; Pearson AD; Eccles SA; Chesler L; George RE
Cancer Cell; 2012 Jul; 22(1):117-30. PubMed ID: 22789543
[TBL] [Abstract][Full Text] [Related]
40. Molecular and genetic bases of neuroblastoma.
Kamijo T; Nakagawara A
Int J Clin Oncol; 2012 Jun; 17(3):190-5. PubMed ID: 22588778
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]